Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2903 | SARS-CoV-2 Wiki | 0.50 |
drug2490 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
To evaluate the safety and tolerability, the antiviral activity, and plasma pharmacokinetics (PK) of zotatifin administered intravenously (IV) to adults with mild or moderate COVID-19.
Description: Incidence of Treatment Emergent Adverse Events and Serious Adverse Events
Measure: Safety as assessed by the incidence of Treatment Emergent Adverse Events and Serious Adverse Events Time: 52 daysDescription: Adverse Events of Special Interest to be assessed: Incidence of hospitalizations incidence of cytokine release syndrome hemophagocytic lymphohistiocytosis acute respiratory distress syndrome need for oxygen supplementation
Measure: Safety as assessed by the incidence of adverse events of special interest: Time: 52 daysDescription: Changes as assessed by respiration rate
Measure: Tolerability as assessed by changes in vital signs from baseline (Day 1) Time: 22 daysDescription: Changes as assessed by heart rate
Measure: Tolerability as assessed by changes in vital signs from baseline (Day 1) Time: 22 daysDescription: Changes as assessed by oxygen saturation
Measure: Tolerability as assessed by changes in vital signs from baseline (Day 1) Time: 22 daysDescription: Changes as assessed by temperature
Measure: Tolerability as assessed by changes in vital signs from baseline (Day 1) Time: 22 daysDescription: Changes as assessed by blood pressure
Measure: Tolerability as assessed by changes in vital signs from baseline (Day 1) Time: 22 daysDescription: Changes as assessed by physical exam
Measure: Tolerability as assessed by changes in clinical symptoms from baseline (Day 1) Time: 22 daysDescription: Changes as assessed by serum chemistry
Measure: Tolerability as assessed by changes in clinical laboratory tests from baseline (Day 1) Time: 22 daysDescription: Changes as assessed by hematology
Measure: Tolerability as assessed by changes in clinical laboratory tests from baseline (Day 1) Time: 22 daysDescription: Changes as assessed by coagulation
Measure: Tolerability as assessed by changes in clinical laboratory tests from baseline (Day 1) Time: 22 daysDescription: Changes as assessed by urinalysis
Measure: Tolerability as assessed by changes in clinical laboratory tests from baseline (Day 1) Time: 22 daysDescription: Defined as the time to the first of 2 consecutive negative SARS-CoV-2 measurements assessed from swab specimen
Measure: Time to viral load undetectability; Time: 22 daysDescription: Assessed by swab specimen
Measure: Proportion of patients with SARS-CoV-2 viral load below the level of detectability; Time: 22 daysDescription: Assessed by swab specimen
Measure: Mean change in SARS-CoV-2 viral load; Time: 22 daysDescription: Defined as resolution of symptoms on the WHO 9-point ordinal scale for clinical improvement.
Measure: The time to clinical resolution; Time: 52 daysDescription: Concentrations at end of infusion, end of dosing interval, and on defined timepoint periods.
Measure: Zotatifin plasma concentrations Time: 15 daysDescription: Time to the first of 2 consecutive negative SARS-CoV-2 measurements assessed from daily samples
Measure: Time to viral load undetectability Time: 22 daysDescription: Assessed from daily saliva and anterior nasal samples
Measure: Proportion of patients below the limit of detection Time: 22 daysDescription: Assessed from daily saliva and anterior nasal samples
Measure: Mean change in viral load in saliva and nasal samples Time: 22 daysDescription: Assessed from plasma collected
Measure: Mean change in viral load in plasma Time: 22 daysDescription: Assessed by plaque-based or comparable assay
Measure: Assessment and quantification of infectious virus Time: 22 daysDescription: According Virus Analysis Plan
Measure: Virus resistance Time: 22 daysDescription: Assessed in change from baseline to post infusion
Measure: Change in the WHO 9-point ordinal scale for clinical improvement Time: 38 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports